ATE510841T1 - Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase - Google Patents

Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Info

Publication number
ATE510841T1
ATE510841T1 AT08762345T AT08762345T ATE510841T1 AT E510841 T1 ATE510841 T1 AT E510841T1 AT 08762345 T AT08762345 T AT 08762345T AT 08762345 T AT08762345 T AT 08762345T AT E510841 T1 ATE510841 T1 AT E510841T1
Authority
AT
Austria
Prior art keywords
disorders
kinase
thiazoliopyrimidines
phosphatidylinositol
kinase inhibitors
Prior art date
Application number
AT08762345T
Other languages
English (en)
Inventor
Timothy Hancox
Neil Pegg
Mandy Beswick
Toby Blench
Elsa Dechaux
Janusz Kulagowski
Alan Nadin
Stephen Price
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0711344A external-priority patent/GB0711344D0/en
Priority claimed from GB0715677A external-priority patent/GB0715677D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE510841T1 publication Critical patent/ATE510841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08762345T 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase ATE510841T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711344A GB0711344D0 (en) 2007-06-12 2007-06-12 Pharmaceutical compounds
GB0715677A GB0715677D0 (en) 2007-08-10 2007-08-10 Pharmaceutical compounds
PCT/GB2008/002014 WO2008152390A1 (en) 2007-06-12 2008-06-12 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Publications (1)

Publication Number Publication Date
ATE510841T1 true ATE510841T1 (de) 2011-06-15

Family

ID=39731164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762345T ATE510841T1 (de) 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Country Status (7)

Country Link
US (2) US7893060B2 (de)
EP (1) EP2158207B1 (de)
JP (1) JP5539190B2 (de)
CN (1) CN101679456B (de)
AT (1) ATE510841T1 (de)
CA (1) CA2692050A1 (de)
WO (1) WO2008152390A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
EP2418223A3 (de) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
CN101679456B (zh) * 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
EP2207781B1 (de) 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidinverbindungen als p13k-inhibitoren und anwendungsverfahren
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
PE20110403A1 (es) 2008-07-31 2011-07-04 Genentech Inc Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2754890C (en) * 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
EP2426135A4 (de) 2009-04-27 2013-02-20 Shionogi & Co Harnstoffderivat mit pi3k-hemmender wirkung
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
JP5781066B2 (ja) 2009-05-27 2015-09-16 ジェネンテック， インコーポレイテッド ｐ１１０δに対して選択的な二環式ピリミジンＰＩ３Ｋ阻害剤化合物及び使用方法
US8828990B2 (en) 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
WO2011058027A2 (en) 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
KR101467858B1 (ko) * 2009-12-28 2014-12-02 재단법인 생물기술개발중심 ｍＴＯＲ 및 ＰＩ３Ｋ 억제제로서의 신규 피리미딘 화합물
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
RU2013104038A (ru) * 2010-07-14 2014-08-20 Ф. Хоффманн-Ля Рош Аг СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
EP2813506B1 (de) 2010-12-16 2016-05-25 F. Hoffmann-La Roche AG Tricyclische PI3K-Hemmerverbindungen und Verfahren zur Verwendung
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP2875018B1 (de) 2012-07-20 2018-02-14 Cleave Biosciences, Inc. Kondensierte pyrimidine als inhibitoren des p97-komplexes
RU2016110852A (ru) * 2013-09-27 2017-10-30 Нимбус Айрис, Инк. Ингибиторы irak и их применения
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
EP3152216B1 (de) 2014-06-05 2019-07-24 Bayer CropScience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
KR101919189B1 (ko) * 2016-02-18 2018-11-15 경북대학교 산학협력단 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
AT321295B (de) * 1971-11-11 1975-03-25 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
PL340589A1 (en) * 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
JP2002540204A (ja) * 1999-03-26 2002-11-26 アストラゼネカ・アクチエボラーグ 新規化合物
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1964946A (zh) * 2004-04-12 2007-05-16 托伦脱药品有限公司 作为hsp 70诱导物的2－丙烯－1－酮
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
EP1912639A4 (de) * 2005-08-08 2011-10-12 Janssen Pharmaceutica Nv Thiazolopyrimidin-kinasehemmer
WO2007122410A1 (en) * 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
ATE532788T1 (de) * 2006-04-26 2011-11-15 Hoffmann La Roche Pharmazeutische verbindungen
NZ572812A (en) * 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
CL2007001166A1 (es) * 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
ES2544082T3 (es) * 2006-12-07 2015-08-27 F. Hoffmann-La Roche Ag Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
EP2114950B1 (de) * 2006-12-07 2016-03-09 Genentech, Inc. Phosphoinositid-3-kinaseinhibitorverbindungen und anwendungsverfahren
CN101679456B (zh) * 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
EP2207781B1 (de) * 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidinverbindungen als p13k-inhibitoren und anwendungsverfahren

Also Published As

Publication number Publication date
US20100190769A1 (en) 2010-07-29
CN101679456B (zh) 2012-09-05
CA2692050A1 (en) 2008-12-18
JP2010529182A (ja) 2010-08-26
JP5539190B2 (ja) 2014-07-02
EP2158207A1 (de) 2010-03-03
CN101679456A (zh) 2010-03-24
US7893060B2 (en) 2011-02-22
US20110098270A1 (en) 2011-04-28
US8168633B2 (en) 2012-05-01
WO2008152390A1 (en) 2008-12-18
EP2158207B1 (de) 2011-05-25

Similar Documents

Publication Publication Date Title
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
DE602008004650D1 (de) Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
MX2009010881A (es) Compuestos farmaceuticos.
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
GB0423653D0 (en) Pharmaceutical compounds
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
ATE543819T1 (de) Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
UY30323A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
WO2009011850A3 (en) Novel therapeutic compounds
EA201000098A1 (ru) Производные хиназолинамида
EA200802329A1 (ru) Производные триазола ii
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
MA32811B1 (fr) Nouveaux composés
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MX2008014500A (es) 2,4-diaminopirimidinas como inhibidores de quinasas de ciclo de celulas.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
SE0301232D0 (sv) Novel use
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
TW200801018A (en) 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
ECSP099046A (es) Derivados ciclopropil amina
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties